Clinical Trial Update: Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating nimotuzumab combined with nab-paclitaxel and gemcitabine for perioperative treatment of high-risk resectable or borderline res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)
• Nimotuzumab (nimotuzumab)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Pancreatic Cancer, Adult | Phase 2 | Status: NOT_YET_RECRUITING